AstraZeneca (NYSE:AZN) says Imfinzi has been granted a priority review by the FDA for the treatment of extensive-stage small cell lung cancer in previously untreated patients.
The type of lung cancer being targeted is considered an aggressive and fast-growing form.
The PDUFA date for the SCLC indication has been set for Q1 of 2020.
Shares of AstraZeneca are down 0.29% in premarket trading.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.